Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Collegium (Nasdaq: COLL) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The session is scheduled for Wednesday, June 3, 2026, at 1:20 p.m. ET, with a live webcast and 90-day replay on the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – COLL
In the May 27 session, COLL declined 0.30%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Acquisition close | Positive | -0.3% | Closed AZSTARYS acquisition, increased 2026 guidance and outlined synergy targets. |
| May 07 | Earnings release | Positive | +7.7% | Reported Q1 2026 results with 9% YoY revenue growth and reaffirmed guidance. |
| Apr 23 | Earnings date set | Neutral | -2.4% | Announced timing of Q1 2026 results and related conference call details. |
| Apr 08 | Investor conferences | Positive | +2.0% | Disclosed participation in Needham and Piper Sandler investor conferences. |
| Mar 19 | Acquisition announced | Positive | +4.3% | Announced plan to acquire AZSTARYS with expectations for EBITDA accretion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions show mostly positive alignment on earnings and M&A, with occasional divergences where constructive updates, including acquisitions and event notices, saw flat-to-negative price moves.
Over the last few months, Collegium has focused on growth and visibility. It announced the $650M AZSTARYS acquisition on Mar 19 and completed it on May 12, raising 2026 revenue guidance to $865–$895M and adjusted EBITDA to $475–$500M. Q1 2026 earnings on May 7 showed $193.5M product revenue and strong JORNAY PM growth. Multiple investor conference appearances, including mid-April events, frame today’s Jefferies participation as part of an ongoing outreach effort.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.
Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
